Jane Grove

Contact

• workRoom WE1379 E floor West Block
  Queen's Medical Centre
  Nottingham
  NG7 2UH
  UK
• work0115 82 31151
• jane.grove@nottingham.ac.uk

Biography

ORCiD:0000-0002-9950-7201

I am an Associate Professor in the Hepatology Group in the Nottingham Digestive Diseases Centre in Translational Medical Sciences and the Gastrointestinal and Liver Disorders Theme of the NIHR Nottingham Biomedical Research Centre. My research includes translational research projects in the following areas:

• Drug-induced liver injury (assessment, genetic and environmental factors that affect drug metabolism and hepatotoxicity).
• Non-alcoholic fatty liver disease and alcoholic liver disease (mechanisms and biomarkers of liver injury including microbiome and metabolomics).
• Genetic determinants of liver disease.
• Development and validation of markers of oxidative stress in the evaluation of acute liver injury and chronic liver diseases.
• Non-invasive assessment of liver fibrosis.
• Clinical application of liver biomarkers.
• Experimental diagnostics of chronic liver injury.

IMI TransBioLine Consortium Research: The TransBioLine project aims to develop novel safety biomarkers that will reliably indicate injury of the liver, kidneys, pancreas, blood vessels, and central nervous system for drug development purposes. By the end of the project, the team will have set up an infrastructure and processes to continue biomarker research across a comprehensive network of industry, academic institutions, and small and medium-sized enterprises, providing to the scientific community, industry and patients with detailed data across a large spectrum of advanced safety biomarkers. (www.Transbioline.com)

I am co-leader for work group 1 of COST ACTION CA17112 - PRO-EURO DILI NETWORK https://www.cost.eu/actions/CA17112

I am involved in collaborative research partnerships with Population Health and Research Institute, Trivandrum, India. ClinicalTrials.gov Identifier: NCT03844165 - Fighting Fatty Liver in India.

I also contributed to the Nottingham Molecular Pathology Node (http://www.nmpn.info/).

Current research studies recruiting participants:

Fatty Liver and Steatohepatitis Study-

This study evaluates possible genetic reasons for the development of non-alcoholic steatohepatitis (NASH), alcoholic steatohepatitis (ASH) and the progression of fatty liver.

Methotrexate Study-

This study investigates the effectiveness of certain non-invasive tests in the detection of liver scarring in patients with rheumatoid arthritis or psoriasis who are currently on methotrexate.

Drug-induced Liver Injury Study-

This is an international Biobank resource to enable research into the causes and characteristics of drug-induced liver injury (DILI) so that new, non-invasive diagnostic tests can be developed. The goal is to predict and prevent drug-induced liver injury (DILI) so patients can be safely treated with medications they need.

Checkpoint Inhibitor-induced Liver Injury (ChILI) - ClinicalTrials.gov Identifier: NCT04476563:

Multi-center prospective observational study to identify the incidence and risk factors for checkpoint inhibitor-induced liver injury and characterize biochemical, genetic, immunological, and histological features associated with it.

Low GI Diet Effects on Non-Alcoholic Fatty Liver Disease (LGI-NAFLD) Study - ClinicalTrials.gov Identifier: NCT04415632.

A 2 x 2 cross-over dietary intervention trial designed to investigate the effects of low glycemic index (LGI) versus high glycemic index (HGI) diet on hepatic fat accumulation and gut microbiota composition in participants with NAFLD.

NDDCBRU Research Tissue Bank-

Nottingham Digestive Diseases Centre Biomedical Research Unit research tissue bank is a local collection of biological samples from patients and research participants to facilitate new research projects investigating digestive health. The aim is to provide high quality biological samples to researchers worldwide for projects to improve the health and care of patients in the future.

Responsibilities:

I am academic lead for postgraduate student training and development in the School of Medicine and a member of the Doctoral Training Committee.

I am the Human Tissue Authority Person Designate for the Nottingham Digestive Diseases Centre and academic representative on the University Biosafety Committee and School of Medicine Safety Committee. (I have Biosafety Practitioner 1 qualification).

I am a member of the UK Stratified Medicine and Pharmacogenetics Committee and am involved in developing Biobank networks.

Research Experience:

Analysis of genetic determinants of the development of alcoholic liver disease. (Newcastle University)

Improvement of E. coli nitroreductase by mutagenesis: a route to optimization of virus- directed enzyme-prodrug cancer therapy. (Cobra Therapeutics)

DNA double-strand break repair in E. coli. (Nottingham University)

Role of novel Type IV secretion systems in Helicobacter pylori virulence. (Nottingham University)

Degree: Molecular Biology and Biochemistry (Durham University)

PGCE: secondary science (University of Nottingham) & Qualified Teacher Status

PhD: Escherichia coli genes essential for formate-dependent nitrite reduction, cytochrome c biosynthesis and periplasmic nitrate reduction. (Birmingham University)

Expertise Summary

Quantification of circulating biomarkers including Luminex multiplex analysis on Bioplex 200

Characterisation and phenotyping of patient cohorts and analysis of clinical data

Expression analyses including assessment of liver tissue markers

Molecular genetics including detection of polymorphisms, cloning, PCR and sequencing

Biochemistry (including protein expression, purification and analysis)

Biobanking: setting up a Research Tissue Bank, clinical sample collection, storage and cataloging/databases

Microbiology: specialist in E.coli and H.pylori manipulation and phenotyping

Research Summary

My research includes translational research projects in the following areas:

• Drug-induced liver injury (assessment, genetic and environmental factors that affect drug metabolism and hepatotoxicity).
• Non-alcoholic fatty liver disease and alcoholic liver disease (mechanisms and biomarkers of liver injury).
• Genetic determinants of liver disease.
• Development and validation of markers of oxidative stress in the evaluation of acute liver injury and chronic liver diseases.
• Non-invasive assessment of liver fibrosis.
• Clinical application of liver biomarkers.
• Experimental diagnostics of chronic liver injury.

Research Experience:

Analysis of genetic determinants of the development of alcoholic liver disease. (Newcastle University)

Improvement of E. coli nitroreductase by mutagenesis: a route to optimization of virus- directed enzyme-prodrug cancer therapy. (Cobra Therapeutics)

DNA double-strand break repair in E. coli. (Nottingham University)

Role of novel Type IV secretion systems in Helicobacter pylori virulence. (Nottingham University)

Degree: Molecular Biology and Biochemistry (Durham University)

PhD: Escherichia coli genes essential for formate-dependent nitrite reduction, cytochrome c biosynthesis and periplasmic nitrate reduction. (Birmingham University)

.

Selected Publications

• ASTBURY, S, GROVE JI, DORWARD DA, GUHA IN and FALLOWFIELD JA, 2021. Reliable computational quantification of liver fibrosis is compromised by inherent staining variation. J Pathol Clin Res. Sep;7(5), 471-481
• NICOLETTI P, DEVARBHAVI H, GOEL A, VENKATESAN R, EAPEN CE, GROVE JI, ZAFER S, BJORNSSON E, LUCENA MI, ANDRADE RJ, PIRMOHAMED M, WADELIUS M, LARREY D, LARREY D, IBANEZ L, WATKINS PB, DALY AK and AITHAL GP, 2021. Genetic Risk Factors in Drug-Induced Liver Injury Due to Isoniazid-Containing Antituberculosis Drug Regimens Clin Pharmacol Ther. 109(4), 1125-1135
• ATKINSON, STEPHEN R, GROVE, JANE I, LIEBIG, STEPHANIE, ASTBURY, STUART, VERGIS, NIKHIL, GOLDIN, ROBERT, QUAGLIA, ALBERTO, BANTEL, HEIKE, GUHA, INDRA NEIL, THURSZ, MARK R, NEWCOMBE, PAUL, STRNAD, PAVEL and AITHAL, GURUPRASAD P, 2020. In Severe Alcoholic Hepatitis, Serum Keratin-18 Fragments Are Diagnostic, Prognostic, and Theragnostic Biomarkers. The American Journal of Gastroenterology. 115(11), 1857-1868
• STICKEL, FELIX, LUTZ, PHILIPP, BUCH, STEPHAN, NISCHALKE, HANS DIETER, SILVA, INES, RAUSCH, VANESSA, FISCHER, JANETT, WEISS, KARL HEINZ, GOTTHARDT, DANIEL, ROSENDAHL, JONAS, MAROT, ASTRID, ELAMLY, MONA, KRAWCZYK, MARCIN, CASPER, MARKUS, LAMMERT, FRANK, BUCKLEY, THOMAS WM, MCQUILLIN, ANDREW, SPENGLER, ULRICH, EYER, FLORIAN, VOGEL, ARNDT, MARHENKE, SILKE, VON FELDEN, JOHANN, WEGE, HENNING, SHARMA, ROHINI, ATKINSON, STEPHEN, FRANKE, ANDRE, NEHRING, SOPHIE, MOSER, VINCENT, SCHAFMAYER, CLEMENS, SPAHR, LAURENT, LACKNER, CAROLIN, STAUBER, RUDOLF E., CANBAY, ALI, LINK, ALEXANDER, VALENTI, LUCA, GROVE, JANE I., AITHAL, GURUPRASAD P., MARQUARDT, JENS U., FATEEN, WALEED, ZOPF, STEFFEN, DUFOUR, JEAN-FRANCOIS, TREBICKA, JONEL, DATZ, CHRISTIAN, DELTENRE, PIERRE, MUELLER, SEBASTIAN, BERG, THOMAS, HAMPE, JOCHEN and MORGAN, MARSHA Y, 2020. Genetic variation in HSD17B13 reduces the risk of developing cirrhosis and hepatocellular carcinoma in alcohol misusers Hepatology. 72(1), 88-102

• View all publications

Past Research

MRC-funded Nottingham Molecular Pathology Node (http://www.nmpn.info/): The Nottingham Molecular Pathology Node for Integrated Multi-platform Biomarker Research and Knowledge Transfer -bringing together informatics, computational modeling and molecular pathology to find new biomarkers for a range of diseases, particularly those affecting the digestive and respiratory systems and the liver.

Role of novel Type IV secretion systems in Helicobacter pylori virulence. (PI Rob Delahay)

DNA double-strand break repair in E. coli. (PI Bob Lloyd)

• GROVE J.I., LO P., SHRINE N., BARWELL J., WAIN L., TOBIN M., ANDREW M. SALTER, HANON N.R.F., AITHAL G.P. and ET AL., 2023. Identification and characterisation of a rare MTTP variant underlying hereditary non-alcoholic fatty liver disease JHEP Reports.
• EDMOND ATALLAH, JANE I. GROVE, COLIN CROOKS, ESTHER BURDEN-TEH, ABHISHEK ABHISHEK, SULLEMAN MOREEA, KELSEY M. JORDAN, AFTAB ALA, DAVID HUTCHINSON, RICHARD J. ASPINALL, RUTH MURPHY and GURUPRASAD P. AITHAL, 2023. Risk of liver fibrosis associated with long-term methotrexate therapy may be overestimated Journal of Hepatology. 78(5), 989-997
• JANE I. GROVE, PEGGY C.K. LO, NICK SHRINE, JULIAN BARWELL, LOUISE V. WAIN, MARTIN D. TOBIN, ANDREW M. SALTER, ADITI N. BORKAR, SARA CUEVAS-OCAÑA, NEIL BENNETT, CATHERINE JOHN, IOANNA NTALLA, GABRIELA E. JONES, CHRISTOPHER P. NEAL, MERVYN G. THOMAS, HELEN KUHT, PANKAJ GUPTA, VISHWARAJ M. VEMALA, ALLISTER GRANT, ADEOLU B. ADEWOYE, KOTACHERRY T. SHENOY, LEENA K. BALAKUMARAN, EDWARD J. HOLLOX, NICHOLAS R.F. HANNAN and GURUPRASAD P. AITHAL, 2023. Identification and characterisation of a rare MTTP variant underlying hereditary non-alcoholic fatty liver disease JHEP Reports. 5(8), 100764
• GAI, ZHIBO, SAMODELOV, SOPHIA L., ALECU, IRINA, HORNEMANN, THORSTEN, GROVE, JANE I., AITHAL, GURUPRASAD P., VISENTIN, MICHELE and KULLAK-UBLICK, GERD A., 2023. Plasma Sphingoid Base Profiles of Patients Diagnosed with Intrinsic or Idiosyncratic Drug-induced Liver Injury International Journal of Molecular Sciences. 24(3),
• LØNSMANN, IDA, GROVE, JANE I., HAIDER, ASMA, KAYE, PHILIP, KARSDAL, MORTEN A., LEEMING, DIANA J. and AITHAL, GURUPRASAD P., 2023. Biomarkers of Type IV Collagen Turnover Reflect Disease Activity in Patients with Early-Stage Non-Alcoholic Fatty Liver (NAFL) Biology. 12(8),
• HASHIM, AHMED, BREMNER, STEPHEN, GROVE, JANE I, ASTBURY, STUART, MENGOZZI, MANUELA, O’SULLIVAN, MARGARET, MACKEN, LUCIA, WORTHLEY, TIM, KATAREY, DEV, AITHAL, GURUPRASAD P and OTHERS, 2022. Chronic liver disease in homeless individuals and performance of non-invasive liver fibrosis and injury markers: VALID study Liver International. 42(3), 628-639
• RAHMAN SR, ROPER JA, GROVE JI, AITHAL GP and BENNETT AJ, 2022. Integrins as a drug target in liver fibrosis Liver International. 42(3), 507-521
• INNES H, WALKER AJ, BENSELIN J, GROVE JI, PEDERGNANA V, AZIM ANSARI M, LIN SK, MCLAUCHLAN J, HUTCHINSON SJ, BARNES E, IRVING WL, GUHA IN and STOP-HCV CONSORTIA, 2022. Comprehensive Comparative Analysis of Standard Validated, Genetic, and Novel Biomarkers to Enhance Prognostic Risk-Stratification in Patients With Hepatitis C Virus Cirrhosis. Clin Transl Gastroenterol.. Feb 9;13(3):e00462,
• VIJAY A, AL-AWADI A, CHALMERS J, BALAKUMARAN L, GROVE JI, VALDES AM, TAYLOR MA, SHENOY KT and AITHAL GP, 2022. Development of Food Group Tree-Based Analysis and Its Association with Non-Alcoholic Fatty Liver Disease (NAFLD) and Co-Morbidities in a South Indian Population: A Large Case-Control Study. Nutrients.
• BJÖRNSSON ES, STEPHENS C, ATALLAH E, ROBLES-DIAZ M, ALVAREZ-ALVAREZ I, GERBES A, WEBER S, STIRNIMANN G, KULLAK-UBLICK G, CORTEZ-PINTO H, GROVE JI, LUCENA MI, ANDRADE RJ and AITHAL GP, 2022. A new framework for advancing in drug-induced liver injury research. The Prospective European DILI Registry.
• ASTBURY, S, GROVE JI, DORWARD DA, GUHA IN and FALLOWFIELD JA, 2021. Reliable computational quantification of liver fibrosis is compromised by inherent staining variation. J Pathol Clin Res. Sep;7(5), 471-481
• SCOTT RA, WILLIAMS HG, HOAD CL, ALYAMI A, ORTORI CA, GROVE JI, MARCIANI L, MORAN GW, MENYS A and AITHAL GP, 2021. MR Measures of Small Bowel Wall T2 Are Associated With Increased Permeability J Magn Reson Imaging. 53(5), 1422-1431
• NICOLETTI P, DEVARBHAVI H, GOEL A, VENKATESAN R, EAPEN CE, GROVE JI, ZAFER S, BJORNSSON E, LUCENA MI, ANDRADE RJ, PIRMOHAMED M, WADELIUS M, LARREY D, LARREY D, IBANEZ L, WATKINS PB, DALY AK and AITHAL GP, 2021. Genetic Risk Factors in Drug-Induced Liver Injury Due to Isoniazid-Containing Antituberculosis Drug Regimens Clin Pharmacol Ther. 109(4), 1125-1135
• MEHTA O, INBARAJ LR, ASTBURY S, GROVE JI, NORMAN G, AITHAL GP, VALDES AM and VIJAY A, 2021. Gut Microbial Profile Is Associated With Residential Settings and Not Nutritional Status in Adults in Karnataka, India. Front Nutr.. 23(8), 595756
• AL-AWADI A, GROVE JI, TAYLOR MA, VALDES AM, VIJAY A, BAWDEN S, GOWLAND P and AITHAL GP, 2021. Effects of an isoenergetic low Glycaemic Index (GI) diet on liver fat accumulation and gut microbiota composition in patients with non-alcoholic fatty liver disease (NAFLD): a study protocol of an efficacy mechanism evaluation. BMJ Open. Oct 7;11(10):e045802,
• STICKEL, FELIX, LUTZ, PHILIPP, BUCH, STEPHAN, NISCHALKE, HANS DIETER, SILVA, INES, RAUSCH, VANESSA, FISCHER, JANETT, WEISS, KARL HEINZ, GOTTHARDT, DANIEL, ROSENDAHL, JONAS, MAROT, ASTRID, ELAMLY, MONA, KRAWCZYK, MARCIN, CASPER, MARKUS, LAMMERT, FRANK, BUCKLEY, THOMAS WM, MCQUILLIN, ANDREW, SPENGLER, ULRICH, EYER, FLORIAN, VOGEL, ARNDT, MARHENKE, SILKE, VON FELDEN, JOHANN, WEGE, HENNING, SHARMA, ROHINI, ATKINSON, STEPHEN, FRANKE, ANDRE, NEHRING, SOPHIE, MOSER, VINCENT, SCHAFMAYER, CLEMENS, SPAHR, LAURENT, LACKNER, CAROLIN, STAUBER, RUDOLF E., CANBAY, ALI, LINK, ALEXANDER, VALENTI, LUCA, GROVE, JANE I., AITHAL, GURUPRASAD P., MARQUARDT, JENS U., FATEEN, WALEED, ZOPF, STEFFEN, DUFOUR, JEAN-FRANCOIS, TREBICKA, JONEL, DATZ, CHRISTIAN, DELTENRE, PIERRE, MUELLER, SEBASTIAN, BERG, THOMAS, HAMPE, JOCHEN and MORGAN, MARSHA Y, 2020. Genetic variation in HSD17B13 reduces the risk of developing cirrhosis and hepatocellular carcinoma in alcohol misusers Hepatology. 72(1), 88-102
• MOOLLA, AHMAD, DE BOER, JASPER, PAVLOV, DAVID, AMIN, AMIN, TAYLOR, ANGELA, GILLIGAN, LORNA, HUGHES, BEVERLY, RYAN, JOHN, BARNES, ELEANOR, HASSAN-SMITH, ZAKI, GROVE, JANE, AITHAL, GURUPRASAD P., VERRIJKEN, AN, FRANCQUE, SVEN, VAN GAAL, LUC, ARMSTRONG, MATTHEW J., NEWSOME, PHILLIP N., COBBOLD, JEREMY F., ARLT, WIEBKE, BIEHL, MICHAEL and TOMLINSON, JEREMY W., 2020. Accurate non-invasive diagnosis and staging of non-alcoholic fatty liver disease using the urinary steroid metabolome ALIMENTARY PHARMACOLOGY & THERAPEUTICS. 51(11), 1188-1197
• VIJAY, AMRITA, MOHAN, LEENA, TAYLOR, MOIRA A., GROVE, JANE I., VALDES, ANA M., AITHAL, GURUPRASAD P. and SHENOY, K. T., 2020. The Evaluation and Use of a Food Frequency Questionnaire Among the Population in Trivandrum, South Kerala, India NUTRIENTS. 12(2), 383
• ATKINSON, STEPHEN R, GROVE, JANE I, LIEBIG, STEPHANIE, ASTBURY, STUART, VERGIS, NIKHIL, GOLDIN, ROBERT, QUAGLIA, ALBERTO, BANTEL, HEIKE, GUHA, INDRA NEIL, THURSZ, MARK R, NEWCOMBE, PAUL, STRNAD, PAVEL and AITHAL, GURUPRASAD P, 2020. In Severe Alcoholic Hepatitis, Serum Keratin-18 Fragments Are Diagnostic, Prognostic, and Theragnostic Biomarkers. The American Journal of Gastroenterology. 115(11), 1857-1868
• PAOLA NICOLETTI, GURUPRASAD P. AITHAL, THOMAS C. CHAMBERLAIN, THOMAS C. CHAMBERLAIN, MOHAMMAD ALSHABEEB, JANE I. GROVE, RAUL J. ANDRADE, EINAR BJORNSSON, JOHN F. DILLON, PAR HALLBERG, M. ISABEL LUCENA, ANKE H. MAITLAND-VAN DER ZEE, JENNIFER H. MARTIN, MARIAM MOLOKHIA, MUNIR PIRMOHAMED, MIA WADELIUS, YUFENG SHEN and MATTHEW R. NELSON, 2019. Drug-induced injury due to flucloxacillin: relevance of multiple HLA alleles Clinical Pharmacology & Therapeutics. 106(1), 245-253
• STUART ASTBURY, EDMOND ATALLAH, AMRITA VIJAY, GURUPRASAD P AITHAL, JANE I GROVE and ANA M VALDES, 2019. Lower gut microbiome diversity and higher abundance of proinflammatory genus Collinsella are associated with biopsy-proven nonalcoholic steatohepatitis Gut Microbes. 11(3), 569-580
• CHALMERS, JANE, BAN, LU, LEENA, KONDARAPASSERY B, EDWARDS, KIMBERLEY L, GROVE, JANE L, AITHAL, GURUPRASAD P and SHENOY, KOTACHERRY T, 2019. Cohort profile: the Trivandrum non-alcoholic fatty liver disease (NAFLD) cohort BMJ Open. 9(5),
• STICKEL, FELIX, LUTZ, PHILIPP, BUCH, STEPHAN, NISCHALKE, HANS DIETER, SILVA, INES, RAUSCH, VANESSA, FISCHER, JANETT, WEISS, KARL HEINZ, GOTTHARDT, DANIEL, ROSENDAHL, JONAS, MAROT, ASTRID, ELAMLY, MONA, KRAWCZYK, MARCIN, CASPER, MARKUS, LAMMERT, FRANK, BUCKLEY, THOMAS WM, MCQUILLIN, ANDREW, SPENGLER, ULRICH, EYER, FLORIAN, VOGEL, ARNDT, MARHENKE, SILKE, VON FELDEN, JOHANN, WEGE, HENNING, SHARMA, ROHINI, ATKINSON, STEPHEN, FRANKE, ANDRE, NEHRING, SOPHIE, MOSER, VINCENT, SCHAFMAYER, CLEMENS, SPAHR, LAURENT, LACKNER, CAROLIN, STAUBER, RUDOLF E, CANBAY, ALI, LINK, ALEXANDER, VALENTI, LUCA, GROVE, JANE I, AITHAL, GURUPRASAD P, MARQUARDT, JENS U, FATEEN, WALEED, ZOPF, STEFFEN, DUFOUR, JEAN-FRANCOIS, TREBICKA, JONEL, DATZ, CHRISTIAN, DELTENRE, PIERRE, MUELLER, SEBASTIAN, BERG, THOMAS, HAMPE, JOCHEN and MORGAN, MARSHA Y, 2019. Genetic variation in HSD17B13 reduces the risk of developing cirrhosis and hepatocellular carcinoma in alcohol misusers. Hepatology (Baltimore, Md.).
• GROVE JI, THIAGARAJAN P, ASTBURY S, HARRIS R, DELAHOOKE T, GUHA IN and AITHAL GP, 2018. Analysis of genotyping for predicting liver injury marker, Procollagen III in persons at risk of non-alcoholic fatty liver disease. Liver International. 38(10), 1832-1838
• KALIYAPERUMAL K, GROVE JI, DELAHAY RM, GRIFFITHS WJH, DUCKWORTH A and AITHAL GP, 2018. Pharmacogenomics of drug-induced liver injury (DILI): Molecular biology to clinical applications. Journal of Hepatology. 69(4), 948-957
• DANIELS SJ, LEEMING DJ, ESLAM M, HASHEM AM, NIELSEN MJ, KRAG A, KARSDAL MA, GROVE JI, GUHA IN, KAWAGUCHI T, TORIMURA T, MCLEOD D, AKIBA J, KAYE P, DE BOER B, AITHAL GP, ADAMS LA and GEORGE J, 2018. ADAPT: An algorithm incorporating PRO-C3 accurately identifies patients with NAFLD and advanced fibrosis. Hepatology. 69(3), 1075-1086
• NICOLETTI P, AITHAL GP, BJORNSSON ES, ANDRADE RJ, SAWLE A, ARRESE M, BARNHART HX, BONDON-GUITTON E, HAYASHI PH, BESSONE F, CARVAJAL A, CASCORBI I, CIRULLI ET, CHALASANI N, CONFORTI A, COULTHARD SA, DALY MJ, DAY CP, DILLON JF, FONTANA RJ, GROVE JI, HALLBERG P, HERNÁNDEZ N, IBÁÑEZ L, KULLAK-UBLICK GA, LAITINEN T, LARREY D, LUCENA MI, MAITLAND-VAN DER ZEE AH, MARTIN JH, MOLOKHIA M, PIRMOHAMED M, POWELL EE, QIN S, SERRANO J, STEPHENS C, STOLZ A, WADELIUS M, WATKINS PB, FLORATOS A, SHEN Y, NELSON MR, URBAN TJ, DALY AK and , 2017. Association of Liver Injury From Specific Drugs, or Groups of Drugs, With Polymorphisms in HLA and Other Genes in a Genome-wide Association Study. Gastroenterology. 152, 1078-1089
• ALANDIYJANY, MAHER N. AND CROXALL, NICOLA J. AND GROVE, JANE I. AND DELAHAY, ROBIN M., 2017. A role for the tfs3 ICE-encoded type IV secretion system in pro-inflammatory signalling by the Helicobacter pylori Ser/Thr kinase, CtkA PLOS ONE. 12(7), 1-16
• GROVE JI, AUSTIN M, TRIBBLE J, AITHAL GP and VERMA S, 2016. Monozygotic twins with NASH cirrhosis: cumulative effect of multiple single nucleotide polymorphisms? Annals of Hepatology. 15(2)(Mar-Apr), 277-82
• GROVE JI and AITHAL GP, 2015. Human leukocyte antigen genetic risk factors of drug-induced liver toxicology. Expert opinion on drug metabolism & toxicology. 11, 395-409
• AITHAL GP and GROVE JI, 2015. Genome-Wide Association Studies in Drug-Induced Liver Injury: Step Change in Understanding the Pathogenesis Semin Liver Dis. 35(04), 421-431
• UPTON AL, GROVE JI, MAHDI AA, BRIGGS GS, MILNER DS, RUDOLPH CJ and LLOYD RG, 2014. Cellular location and activity of Escherichia coli RecG proteins shed light on the function of its structurally unresolved C-terminus. Nucleic acids research. 42(9), 5702-5714
• GROVE, J.I., ALANDIYJANY, M.N. and DELAHAY, R.M., 2013. Site-specific relaxase activity of a VirD2-like protein encoded within the tfs4 genomic island of helicobacter pylori The Journal of Biological Chemistry. 288(37), 26385-26396
• JABERIPOUR M, VASS SO, GUISE CP, GROVE JI, KNOX RJ, HU L, HYDE EI and SEARLE PF, 2010. Testing double mutants of the enzyme nitroreductase for enhanced cell sensitisation to prodrugs: effects of combining beneficial single mutations. Biochemical pharmacology. 79(2), 102-11
• GROVE JI, WOOD SR, BRIGGS GS, OLDHAM NJ and LLOYD RG, 2009. A soluble RecN homologue provides means for biochemical and genetic analysis of DNA doublestrand break repair in Escherichia coli DNA Repair. 8, 1433-1442
• GROVE JI, WOOD SR, BRIGGS GS, OLDHAM NJ and LLOYD RG, 2009. A soluble RecN homologue provides means for biochemical and genetic analysis of DNA double-strand break repair in Escherichia coli. DNA repair. 8(12), 1434-43
• GROVE JI, HARRIS L, BUCKMAN C and LLOYD RG, 2008. DNA double strand break repair and crossing over mediated by RuvABC resolvase and RecG translocase. DNA repair. 7(9), 1517-30
• RACE PR, LOVERING AL, WHITE SA, GROVE JI, SEARLE PF, WRIGHTON CW and HYDE EI, 2007. Kinetic and structural characterisation of Escherichia coli nitroreductase mutants showing improved efficacy for the prodrug substrate CB1954. Journal of molecular biology. 368(2), 481-92
• GUISE CP, GROVE JI, HYDE EI and SEARLE PF, 2007. Direct positive selection for improved nitroreductase variants using SOS triggering of bacteriophage lambda lytic cycle. Gene therapy. 14(8), 690-8
• MEDDOWS, T.R., SAVORY, A.P., GROVE, J.I., MOORE, T. and LLOYD, R.G., 2005. RecN protein and transcription factor DksA combine to promote faithful recombinational repair of DNA double-strand breaks Molecular Microbiology. 57(1), 97-110
• SEARLE PF, CHEN M, HU L, RACE PR, LOVERING AL, GROVE JI, GUISE C, JABERIPOUR M, JAMES ND, MAUTNER V, YOUNG LS, KERR DJ, MOUNTAIN A, WHITE SA and HYDE EI, 2004. Nitroreductase: a prodrug-activating enzyme for cancer gene therapy. Clinical and experimental pharmacology & physiology. 31(11), 811-6
• GROVE JI, LOVERING AL, GUISE C, RACE PR, WRIGHTON CJ, WHITE SA, HYDE EI and SEARLE PF, 2003. Generation of Escherichia coli nitroreductase mutants conferring improved cell sensitization to the prodrug CB1954. Cancer research. 63(17), 5532-7
• GROVE J, DALY AK, BASSENDINE MF, GILVARRY E and DAY CP, 2000. Interleukin 10 promoter region polymorphisms and susceptibility to advanced alcoholic liver disease. Gut. 46(4), 540-5
• GROVE JI, SEARLE PF, WEEDON SJ, GREEN NK, MCNEISH IA and KERR DJ, 1999. Virus-directed enzyme prodrug therapy using CB1954. Anti-cancer drug design. 14(6), 461-72
• EAVES DJ, GROVE J, STAUDENMANN W, JAMES P, POOLE RK, WHITE SA, GRIFFITHS I and COLE JA, 1998. Involvement of products of the nrfEFG genes in the covalent attachment of haem c to a novel cysteine-lysine motif in the cytochrome c552 nitrite reductase from Escherichia coli. Molecular microbiology. 28(1), 205-16
• GROVE J, DALY AK, BURT AD, GUZAIL M, JAMES OF, BASSENDINE MF and DAY CP, 1998. Heterozygotes for HFE mutations have no increased risk of advanced alcoholic liver disease. Gut. 43(2), 262-6
• FRAYLING T, ELLARD S, GROVE J, WALKER M and HATTERSLEY AT, 1998. C282Y mutation in HFE (haemochromatosis) gene and type 2 diabetes. Lancet. 351(9120), 1933-4
• GROVE J, BROWN AS, DALY AK, BASSENDINE MF, JAMES OF and DAY CP, 1998. The RsaI polymorphism of CYP2E1 and susceptibility to alcoholic liver disease in Caucasians: effect on age of presentation and dependence on alcohol dehydrogenase genotype. Pharmacogenetics. 8(4), 335-42
• GROVE J, DALY AK, BASSENDINE MF and DAY CP, 1997. Association of a tumor necrosis factor promoter polymorphism with susceptibility to alcoholic steatohepatitis. Hepatology (Baltimore, Md.). 26(1), 143-6
• GROVE J, TANAPONGPIPAT S, THOMAS G, GRIFFITHS L, CROOKE H and COLE J, 1996. Escherichia coli K-12 genes essential for the synthesis of c-type cytochromes and a third nitrate reductase located in the periplasm. Molecular microbiology. 19(3), 467-81
• IOBBI-NIVOL C, CROOKE H, GRIFFITHS L, GROVE J, HUSSAIN H, POMMIER J, MEJEAN V and COLE JA, 1994. A reassessment of the range of c-type cytochromes synthesized by Escherichia coli K-12. FEMS microbiology letters. 119(1-2), 89-94
• DARWIN A, HUSSAIN H, GRIFFITHS L, GROVE J, SAMBONGI Y, BUSBY S and COLE J, 1993. Regulation and sequence of the structural gene for cytochrome c552 from Escherichia coli: not a hexahaem but a 50 kDa tetrahaem nitrite reductase. Molecular microbiology. 9(6), 1255-65
• AITHAL GP and GROVE JI, Mechanisms of alcohol toxicity. In: NEUBERGER J, ed., Alcohol abuse and liver disease 55-64